|Classification and external resources|
Cutaneous leishmaniasis in the hand of a Central American adult
|DiseasesDB||3266 29171 3266 7070|
Leishmaniasis // or leishmaniosis (// or //) is a disease caused by protozoan parasites of the genus Leishmania and spread by the bite of certain types of sandflies. The disease can present in three main ways as: cutaneous leishmaniasis, mucocutaneous leishmaniasis and visceral leishmaniasis. The cutaneous form presents with skin ulcers, while the mucocutaneous form presents with ulcers of the skin, mouth and nose and the visceral form starts with skin ulcers and then later presents with fever, low red blood cells, and a large spleen and liver.
Infections in humans are caused by more than 20 species of Leishmania. Risk factors include: poverty, malnutrition, deforestation and urbanization. All three types can be diagnosed by directly seeing the parasites under the microscope. Additionally visceral disease can be diagnosed via blood tests.
Leishmaniasis can be partly prevented by sleeping under nets treated with insecticide. Other measures include: spraying insecticides to kill sandflies and treating people with the disease early to prevent further spread. The treatment needed is determined by where the disease is acquired, the species of Leishmania and the type of infection. Some possible medications used for visceral disease include: liposomal amphotericin B, a combination of pentavalent antimonials and paromomycin, and miltefosine. For cutaneous disease paromomycin, fluconazole or pentamidine may be effective.
About 12 million people are currently infected in some 98 countries. There are about 2 million new cases and between 20 to 50 thousand deaths a year. About 200 million people in Asia, Africa, South and Central America and southern Europe live in areas where the disease is common. The World Health Organization has obtained discounts on some medications to treat the disease. The disease may occur in a number of other animals including dogs and rodents.
The symptoms of leishmaniasis are skin sores which erupt weeks to months after the person is bitten by infected sand flies.
Leishmaniasis may be divided into the following types:
Leishmaniasis is considered one of the classic causes of a markedly enlarged (and therefore palpable) spleen; the organ, which is not normally felt during examination of the abdomen, may even become larger than the liver in severe cases.
Leishmaniasis is transmitted by the bite of infected female phlebotomine sandflies. Which can transmit the infection Leishmania. The sandflies inject the infective stage, metacyclic promastigotes, during blood meals (1). Metacyclic promastigotes that reach the puncture wound are phagocytized by macrophages (2) and transform into amastigotes (3). Amastigotes multiply in infected cells and affect different tissues, depending in part on which Leishmania species is involved (4). These differing tissue specificities cause the differing clinical manifestations of the various forms of leishmaniasis. Sandflies become infected during blood meals on infected hosts when they ingest macrophages infected with amastigotes (5,6). In the sandfly's midgut, the parasites differentiate into promastigotes (7), which multiply, differentiate into metacyclic promastigotes, and migrate to the proboscis (8).
The genomes of three Leishmania species (L. major, L. infantum, and L. braziliensis) have been sequenced and this has provided much information about the biology of the parasite. For example, in Leishmania, protein-coding genes are understood to be organized as large polycistronic units in a head-to-head or tail-to-tail manner; RNA polymerase II transcribes long polycistronic messages in the absence of defined RNA pol II promoters, and Leishmania has unique features with respect to the regulation of gene expression in response to changes in the environment. The new knowledge from these studies may help identify new targets for urgently needed drugs and aid the development of vaccines.
Although most of the literature mentions only one genus transmitting Leishmania to humans (Lutzomyia) in the US, a 2003 study by Galati suggested a new classification for American sand flies, elevating several subgenera to the genus level. Elsewhere in the world, the genus Phlebotomus is considered the vector of leishmaniasis.
Visceral disease is usually cause by Leishmania donovani, Leishmania infantum or Leishmania chagasi. But occasionally these species may cause other forms of disease. The cutaneous form of the disease is caused by more than 15 types of Leishmania.
Risk factors include: poverty, malnutrition, deforestation and urbanization.
Leishmaniasis is diagnosed in the haematology laboratory by direct visualization of the amastigotes (Leishman-Donovan bodies). Buffy-coat preparations of peripheral blood or aspirates from marrow, spleen, lymph nodes, or skin lesions should be spread on a slide to make a thin smear and stained with Leishman's or Giemsa's stain (pH 7.2) for 20 minutes. Amastigotes are seen with monocytes or, less commonly in neutrophils, of peripheral blood and in macrophages in aspirates. They are small, round bodies 2–4 μm in diameter with indistinct cytoplasm, a nucleus, and a small, rod-shaped kinetoplast. Occasionally, amastigotes may be seen lying free between cells. However, the retrieval of tissue samples is often painful for the patient and it can be difficult to identify the infected cells. For these reasons, other indirect immunological methods of diagnosis are developed. These methods include the enzyme-linked immunosorbent assay (ELISA), antigen coated dipsticks, and the direct agglutination test (DAT). Although these tests are readily available, they are not the standard diagnostic tests due to their insufficient sensitivity and specificity.
Most forms of the disease are transmitted only from non-human animals, but some can be spread between humans. Infections in humans are caused by about 21 of 30 species that infect mammals: the different species look the same, but they can be differentiated by isoenzyme analysis, DNA sequence analysis, or monoclonal antibodies.
The treatment is determined by where the disease is acquired, the species of Leishmania and the type of infection. For visceral leishmaniasis in India, South America and the Mediterranean liposomal amphotericin B is the recommended treatment and is often affected as a single dose. Rates of cure with a single dose of amphotericin has been reported as 95%. In India almost all infections are resistant to pentavalent antimonials. In Africa a combination of pentavalent antimonials and paromomycin is recommended. These however can have significant side effects. Miltefosine is an oral medication that is effective against both visceral and cutaneous leishmaniasis. Side effects are generally mild, though it can cause birth defects if taken within 3 months of getting pregnant. It does not appear to work for Leishmania major or L. braziliensis.
The evidence around the treatment of cutaneous leishmaniasis is poor. A number of topical treatment may be used for cutaneous leishmaniasis. Which are effects is dependent on the strain with topical paromomycin effective for L. major, L. tropica, L. mexicana, L. panamensis and L. braziliensis. Pentamidine is effective for L. guyanensis. Oral fluconazole or itraconazole appears effective in L. major and L. tropica.
Leishmaniasis occurs in 88 tropical and subtropical countries. Approximately 350 million people live in these areas. The settings in which leishmaniasis is found range from rainforests in Central and South America to deserts in West Asia and the Middle East. It affects as many as 12 million people worldwide, with 1.5–2 million new cases each year. The visceral form of leishmaniasis has an estimated incidence of 500,000 new cases. More than 90 percent of the world's cases of visceral leishmaniasis are in India, Bangladesh, Nepal, Sudan, and Brazil. As of 2010 it caused about 52,000 deaths down from 87,000 in 1990. Different types of the disease occur in different regions of the world. Cutaneous disease is most common in Afghanistan, Algeria, Brazil, Colombia and Iren while mucocutaneous disease is most common in Bolivia, Brazil and Peru and visceral disease is most common in Bangladesh, Brazil, Ethiopia, India and Sudan.
Leishmaniasis is found through much of the Americas from northern Argentina to southern Texas, though not in Uruguay or Chile, and has recently been shown to be spreading to North Texas. Leishmaniasis is also known as papalomoyo, papa lo moyo, ulcero de los chicleros and "chiclera" in Latin America. During 2004, an estimated 3,400 troops from the Colombian army, operating in the jungles near the south of the country (in particular around the Meta and Guaviare departments), were infected with leishmaniasis. Apparently, a contributing factor was that many of the affected soldiers did not use the officially provided insect repellent, because of its allegedly disturbing odor. Nearly 13,000 cases of the disease were recorded in all of Colombia throughout 2004, and about 360 new instances of the disease among soldiers had been reported in February 2005.
The disease is found across much of Asia, and in the Middle East. Within Afghanistan, leishmaniasis occurs commonly in Kabul, partly due to bad sanitation and waste left uncollected in streets, allowing parasite-spreading sand flies an environment they find favorable. In Kabul, the number of people infected was estimated to be at least 200,000, and in three other towns (Herat, Kandahar and Mazar-i-Sharif) there were about 70,000 more, according to WHO figures from 2002.[verification needed] Kabul is estimated as the largest center of cutaneous leishmaniasis in the world, with approximately 67,500 cases as of 2004.
Leishmaniasis is mostly a disease of the developing world, and is rarely known in the developed world outside a small number of cases, mostly in instances where troops are stationed away from their home countries. Leishmaniasis has been reported by U.S. troops stationed in Saudi Arabia and Iraq since the Gulf War of 1990, including visceral leishmaniasis. In September 2005, the disease was contracted by at least four Dutch marines who were stationed in Mazari Sharif, Afghanistan, and subsequently repatriated for treatment.
Descriptions of conspicuous lesions similar to cutaneous leishmaniasis (CL) appear on tablets from King Ashurbanipal from the seventh century BC, some of which may have derived from even earlier texts from 1500 to 2500 BC. Persian physicians, including Avicenna in the 10th century AD, gave detailed descriptions of what was called Balkh sore. In 1756, Alexander Russell, after examining a Turkish patient, gave one of the most detailed clinical descriptions of the disease. Physicians in the Indian subcontinent would describe it as kala-azar (pronounced kālā āzār, the Urdu, Hindi and Hindustani phrase for "black fever", kālā meaning black and āzār meaning fever or disease). In the Americas, evidence of the cutaneous form of the disease in Ecuador and Peru appears in pre-Inca potteries depicting skin lesions and deformed faces dating back to the first century AD. Some 15th- and 16th-century texts from the Inca period and from Spanish colonials mention "valley sickness", "Andean sickness", or "white leprosy", which are likely to be CL.
It remains unclear who first discovered the organism. Surgeon Major Cunningham of the British Indian army possibly saw it first in 1885 without being able to relate it to the disease. Peter Borovsky, a Russian military surgeon working in Tashkent, conducted research into the etiology of oriental sore, locally known as "Sart sore", and in 1898 published the first accurate description of the causative agent, correctly described the parasite's relation to host tissues and correctly referred it to Protozoa. However, because his results were published in Russian in a journal with low circulation, his priority was not internationally acknowledged during his lifetime. In 1901, Leishman identified certain organisms in smears taken from the spleen of a patient who had died from "dum-dum fever" (Dum Dum is an area close to Calcutta) and proposed them to be trypanosomes, found for the first time in India. A few months later, Captain Charles Donovan (1863–1951) confirmed the finding of what became known as Leishman-Donovan bodies in smears taken from patients in Madras in southern India. But it was Ronald Ross who proposed that Leishman-Donovan bodies were the intracellular stages of a new parasite, which he named Leishmania donovani. The link with the disease kala-azar was first suggested by Charles Donovan, but was conclusively demonstrated by Charles Bentley's discovery of Leishmania donovani in patients with kala-azar. The disease became a major problem for Allied troops fighting in Sicily during the Second World War; research by Leonard Goodwin then showed pentostam was an effective treatment.
The Institute for OneWorld Health has reintroduced the drug paromomycin for treatment of leishmaniasis, results with which led to its approval as an orphan drug. The Drugs for Neglected Diseases Initiative is also actively facilitating the search for novel therapeutics. A treatment with paromomycin will cost about $10. The drug had originally been identified in 1960s, but had been abandoned because it would not be profitable, as the disease mostly affects poor people. The Indian government approved paromomycin for sale in August 2006.
The World Health Organization has gotten a reduced cost for liposomal amphotericin B at $18 an vial, however many vials may be needed for treatment and it must be kept cool.
Several potential vaccines are being developed, under pressure from the World Health Organization, but as of 2013[update] none are available. The team at the Laboratory for Organic Chemistry at the Swiss Federal Institute of Technology (ETH) in Zürich are trying to design a carbohydrate-based vaccine. The genome of the parasite Leishmania major has been sequenced, possibly allowing for identification of proteins that are used by the pathogen but not by humans; these proteins are potential targets for drug treatments.
On February 2012, the nonprofit Infectious Disease Research Institute launched the world’s first human clinical trial of the visceral leishmaniasis vaccine. The vaccine is a recombinant form of two fused Leishmania parasite proteins with an adjuvant. Two phase 1 clinical trials with healthy volunteers are to be conducted. The first one takes place in Washington (state) and is followed by a trial in India.
In 2009, the Hebrew University of Jerusalem Kuvin Center for the Study of Infectious and Tropical Diseases, in a collaborative effort with Addis Ababa University, was awarded a grant by the Bill & Melinda Gates Foundation for research into visceral leishmaniasis in Ethiopia. The project will gather data to be analyzed to identify the weak links in the transmission cycle, and devise methods for control of the disease.
HIV protease inhibitors have been found to be active against Leishmania species in two in vitro studies in Canada and India. The studies reported the intracellular growth of parasites was controlled by nelfinavir and ritonavir in a human monocyte cell line and also in human primary monocyte-derived macrophages.
Magazine photographer Joel Sartore was diagnosed with the disease after a skin lesion refused to heal following a photo shoot in the Bolivian wilderness. Following intensive IV treatment similar to chemotherapy, his infection has resolved.
While filming the latest series of Extreme Dreams in Peru, UK television presenter Ben Fogle caught the disease. He was left bedridden for three weeks on his return home. Fogle was treated at London's Hospital for Tropical Diseases.
During his two-and-a-half-year walk through the Amazon, Ed Stafford tested positive for cutaneous leishmaniasis in Oriximiná, Para, Brazil. He convinced the local doctor that he could not stay in one place for treatment due to his undertaking and was prescribed with 20 days of intravenous injections that he self-administered in the jungle.
|isbn=value (help). OCLC 35161690.
Mashpedia enables any individual or company to promote their own Youtube-hosted videos or Youtube Channels, offering a simple and effective plan to get them in front of our engaged audience.
Want to learn more? Please contact us at: email@example.com